MTOR and neoplasm: The activity of S6 was lower in climacostol-injected tumours (at day 16 of treatment) while phosphorylated AMPKα increased (Fig. 7b), thus confirming that climacostol inhibits and stimulates mTOR and AMPK pathways, respectively.